If you've shopped for GLP-1 weight loss medication online, you've encountered two fundamentally different products being marketed side by side — sometimes on the same website, sometimes without clear differentiation. One is an FDA-approved medication backed by large-scale clinical trials. The other is a compounded version prepared by a pharmacy that has not undergone FDA review for safety or effectiveness.
Both exist legally. Both are prescribed by licensed clinicians. But the differences between them are significant, and many telehealth platforms aren't explaining those differences clearly — which is exactly why the FDA has sent warning letters to dozens of companies in 2025 and 2026.
This article explains the actual differences so you can make informed decisions about your treatment.
What "FDA-Approved" Means — and Why It Matters
When a drug receives FDA approval, it means the manufacturer has submitted extensive data from clinical trials demonstrating that the medication is safe and effective for its intended use. The FDA reviews this data, inspects manufacturing facilities, evaluates the labeling, and monitors the drug after approval through adverse event reporting systems.
For GLP-1 weight loss medications, the FDA-approved options as of May 2026 include Wegovy (semaglutide injection and oral tablet), Zepbound (tirzepatide injection), and Foundayo (orforglipron oral tablet). Each of these went through Phase 1, 2, and 3 clinical trials involving thousands of participants, with results published in peer-reviewed journals and reviewed by FDA advisory committees.
The key phrase is "evaluated for safety and effectiveness." This doesn't mean the drugs are risk-free — all medications carry risks — but it means those risks have been characterized, quantified, and weighed against documented benefits by an independent regulatory body.
What "Compounded" Means — and What It Doesn't
Compounding is a legitimate, well-established practice in pharmacy. When a patient needs a medication in a form that isn't commercially available — a different dosage strength, a liquid version of a tablet, or a formulation without a specific allergen — a compounding pharmacy can prepare it.
Compounded GLP-1 medications typically use the same active pharmaceutical ingredient (API) as their FDA-approved counterparts — semaglutide or tirzepatide — but are prepared by a compounding pharmacy rather than the original manufacturer. They have not been evaluated by the FDA for safety, effectiveness, or manufacturing quality.
This doesn't mean compounded medications are inherently dangerous. Millions of compounded prescriptions are safely dispensed every year for conditions across all areas of medicine. But it does mean that the consumer assumes a different risk profile, and understanding that difference is essential to informed consent.
Side-by-Side Comparison
| Factor | FDA-Approved | Compounded |
|---|---|---|
| Clinical trials | Evaluated in Phase 1–3 trials with thousands of participants | No independent trials; relies on research conducted for the approved version |
| FDA oversight | Manufacturing facilities inspected regularly by FDA; adverse events tracked nationally | 503B outsourcing facilities registered with FDA; 503A pharmacies regulated primarily by states |
| Quality assurance | Manufactured under Current Good Manufacturing Practices (cGMP) with rigorous batch testing | Quality varies by pharmacy; no standardized federal manufacturing requirements for 503A pharmacies |
| Dosing precision | Pre-filled pens or tablets manufactured to exact specifications | May require patient to draw from a vial; dosing accuracy depends on pharmacy preparation and patient technique |
| Active ingredient source | Manufactured in-house or sourced from FDA-inspected suppliers | Active ingredient sourced from third-party suppliers; quality depends on the pharmacy's sourcing practices |
| Cost (typical self-pay) | $149–$349/month with manufacturer savings programs; $1,000+/month at list price | $150–$400/month through telehealth platforms |
| Insurance coverage | Covered by some commercial plans and increasingly by Medicare (July 2026 bridge program) | Generally not covered by insurance |
| Availability | Available through retail pharmacies and manufacturer direct programs | Primarily through telehealth platforms partnered with compounding pharmacies |
The Price Question
Cost is the primary reason most consumers consider compounded GLP-1 medications. When brand-name Wegovy and Zepbound carried list prices of $1,000+ per month and insurance coverage was limited, compounded alternatives at $200–$400 per month filled a genuine access gap.
That pricing landscape has shifted meaningfully in 2026. Manufacturer savings programs now bring the self-pay cost of brand-name medications much closer to compounded pricing. Eli Lilly's Foundayo starts at $149 per month through LillyDirect. Novo Nordisk offers Wegovy oral tablets starting at $149 per month for introductory doses. Zepbound is available starting at $399 per month with savings cards.
The gap hasn't closed entirely — particularly at higher doses, where brand-name costs rise to $299–$449 per month while some compounded options remain below $300. But the once-dramatic price advantage of compounding has narrowed considerably, and for patients on lower doses, FDA-approved medications may now be cost-competitive or even cheaper.
Medicare coverage is also expanding. The Medicare GLP-1 Bridge program, scheduled to begin in July 2026, will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 medications. While details are still being finalized, this represents the first time Medicare has covered anti-obesity medications, and it could further reduce the cost advantage of compounded alternatives for the Medicare population.
What the FDA Is Actually Concerned About
The FDA's enforcement actions in 2025–2026 have focused on specific marketing practices, not on the existence of compounding itself. Understanding what the FDA objects to — and what it doesn't — helps separate legitimate concerns from noise.
What the FDA is targeting
Equivalence claims. Marketing that implies compounded semaglutide is "the same as" Wegovy, or that compounded tirzepatide is interchangeable with Zepbound. The FDA considers these claims misleading because compounded products haven't undergone the testing required to make such assertions.
Obscured sourcing. Telehealth companies branding compounded products with their own trade names, implying they manufacture the medication when they don't. This prevents consumers from independently verifying the actual source of their medication.
Safety and efficacy claims. Marketing language that suggests compounded products have been evaluated for safety or effectiveness by the FDA, or that references clinical trial data for approved products as if it applies directly to the compounded version.
What the FDA is not saying
The FDA has not said that compounded GLP-1 medications should be banned entirely. The agency has not said that all telehealth prescribing is problematic. And the FDA has not said that patients currently on compounded medications should immediately stop taking them.
The enforcement focus is on marketing transparency, not on criminalizing patient access. This distinction matters because some media coverage and industry commentary has characterized the crackdown in more extreme terms than the FDA's own statements support.
Safety Considerations That Are Genuinely Different
Setting aside marketing claims, there are real differences in the safety profile of compounded vs. FDA-approved GLP-1 medications that informed consumers should understand:
Sterility and contamination. Injectable medications must be prepared under sterile conditions. FDA-approved products are manufactured in facilities subject to rigorous and regular inspection. Compounding pharmacies are inspected less frequently, and the rigor of sterile preparation varies. The FDA has historically documented contamination issues in compounding pharmacies that have led to serious patient harm — most notably the 2012 fungal meningitis outbreak linked to the New England Compounding Center, which killed 76 people and sickened hundreds. That was an extreme case, but it illustrates why manufacturing standards matter for injectable medications.
Dosing accuracy. FDA-approved GLP-1 injections come in pre-filled pens designed to deliver precise doses. Compounded versions typically come in multi-dose vials that require patients to draw the correct amount with a syringe. Dosing errors are possible, particularly for patients unfamiliar with injection technique.
Active ingredient identity. The FDA has raised concerns about some compounded products using salt forms of semaglutide (such as semaglutide sodium) that differ from the form used in the approved product. The agency has stated that semaglutide sodium is not an acceptable form for compounding because it has not been adequately characterized for safety.
Adverse event reporting. When a patient experiences a side effect from an FDA-approved medication, it enters a national reporting system (FDA Adverse Event Reporting System, or FAERS) that helps identify safety signals across the population. Adverse events from compounded medications are less consistently reported, making it harder to identify patterns.
Questions to Ask Your Provider
Regardless of whether you're leaning toward FDA-approved or compounded medication, these questions will help you have a more informed conversation with your telehealth provider:
If recommending compounded medication: Which pharmacy compounds it? Is it a 503A or 503B facility? What form of semaglutide or tirzepatide does it use — and has the FDA raised any concerns about that form? Does the pharmacy conduct third-party potency and sterility testing? What happens if I experience a problem with the medication?
If recommending FDA-approved medication: Which savings programs am I eligible for? What will my actual out-of-pocket cost be at maintenance dose — not just the introductory dose? Does the platform help with prior authorization if I want to use insurance? What are the realistic timelines for insurance coverage, given that not all plans cover weight loss indications?
For either option: Why are you recommending this specific product over the alternatives? What does follow-up care look like during dose titration? How do I reach you if I have side effects between scheduled visits?
The Bottom Line
The choice between compounded and FDA-approved GLP-1 medications is not a simple good-vs-bad decision. It involves weighing cost, access, safety margins, and personal comfort with different levels of regulatory oversight. Both options exist legally and serve patients effectively when administered properly.
What you deserve — and what the FDA is working to ensure — is honest information to make that choice. If your telehealth provider treats compounded and FDA-approved medications as interchangeable in its marketing, or if it obscures where your medication actually comes from, that's not a provider acting in your best interest. Transparency isn't optional when it comes to what you're putting in your body.